Sherr CJ - Search Results

1

Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization.

Diehl JA, Cheng M, Roussel MF, Sherr CJ. Diehl JA, et al. Among authors: sherr cj. Genes Dev. 1998 Nov 15;12(22):3499-511. doi: 10.1101/gad.12.22.3499. Genes Dev. 1998. PMID: 9832503 Free PMC article.

2

CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma.

Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. Huang CH, et al. Among authors: sherr cj. Genes Dev. 2014 Aug 15;28(16):1800-14. doi: 10.1101/gad.244368.114. Genes Dev. 2014. PMID: 25128497 Free PMC article.

3

Hzf, a p53-responsive gene, regulates maintenance of the G2 phase checkpoint induced by DNA damage.

Sugimoto M, Gromley A, Sherr CJ. Sugimoto M, et al. Among authors: sherr cj. Mol Cell Biol. 2006 Jan;26(2):502-12. doi: 10.1128/MCB.26.2.502-512.2006. Mol Cell Biol. 2006. PMID: 16382142 Free PMC article.

4

N-Myc and the cyclin-dependent kinase inhibitors p18Ink4c and p27Kip1 coordinately regulate cerebellar development.

Zindy F, Knoepfler PS, Xie S, Sherr CJ, Eisenman RN, Roussel MF. Zindy F, et al. Among authors: sherr cj. Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11579-83. doi: 10.1073/pnas.0604727103. Epub 2006 Jul 24. Proc Natl Acad Sci U S A. 2006. PMID: 16864777 Free PMC article.

5

A New Cell-Cycle Target in Cancer - Inhibiting Cyclin D-Dependent Kinases 4 and 6.

Sherr CJ. Sherr CJ. N Engl J Med. 2016 Nov 17;375(20):1920-1923. doi: 10.1056/NEJMp1612343. N Engl J Med. 2016. PMID: 27959598 No abstract available.

6

Differential post-transcriptional regulation of two Ink4 proteins, p18 Ink4c and p19 Ink4d.

Forget A, Ayrault O, den Besten W, Kuo ML, Sherr CJ, Roussel MF. Forget A, et al. Among authors: sherr cj. Cell Cycle. 2008 Dec;7(23):3737-46. doi: 10.4161/cc.7.23.7187. Epub 2008 Dec 13. Cell Cycle. 2008. PMID: 19029828 Free PMC article.

7

An Arf(GFP/GFP) reporter mouse reveals that the Arf tumor suppressor monitors latent oncogenic signals in vivo.

Sherr CJ. Sherr CJ. Cell Cycle. 2004 Mar;3(3):239-40. doi: 10.4161/cc.3.3.674. Epub 2004 Mar 1. Cell Cycle. 2004. PMID: 14726696

8

Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3.

Kuo ML, den Besten W, Thomas MC, Sherr CJ. Kuo ML, et al. Among authors: sherr cj. Cell Cycle. 2008 Nov 1;7(21):3378-87. doi: 10.4161/cc.7.21.6930. Epub 2008 Nov 4. Cell Cycle. 2008. PMID: 18948745

9

Monoclonal antibodies to the mouse p19(Arf) tumor suppressor protein.

Bertwistle D, Zindy F, Sherr CJ, Roussel MF. Bertwistle D, et al. Among authors: sherr cj. Hybrid Hybridomics. 2004 Oct;23(5):293-300. doi: 10.1089/hyb.2004.23.293. Hybrid Hybridomics. 2004. PMID: 15672607

10

N-Terminal polyubiquitination of the ARF tumor suppressor, a natural lysine-less protein.

Kuo ML, den Besten W, Sherr CJ. Kuo ML, et al. Among authors: sherr cj. Cell Cycle. 2004 Nov;3(11):1367-9. doi: 10.4161/cc.3.11.1244. Epub 2004 Nov 15. Cell Cycle. 2004. PMID: 15467472

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results